Edwards Larry Todd — SEC Form 4 filings
SEC reporting owner CIK 1994805. 12 Form 4 filings on record with FilingPulse; latest filed 2026-08-25.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-01-17 to 2026-08-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,093 shares, $7,767 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 10 legs across 8 filings — 60,363 shares, $1,206,684 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 29,131 shares @ $25.16 ($732,927) in Arcutis Biotherapeutics, Inc., filed 2025-11-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | See Remarks | 11 | 1 leg · 1,093 sh · $7,767 | 10 legs · 60,363 sh · $1,206,684 | 9 |
| Oruka Therapeutics, Inc. (ORKA) | Chief Commercial Officer | 1 | — | — | 2 |
Form 4 filings — Edwards Larry Todd
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-25 | 4 | Oruka Therapeutics, Inc. (ORKA) | Grant/award (A): 100,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 30,000 @ $0 · Sale (S): 3,584 @ $25.16 · Sale (S): 103 @ $25.91 · Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 2,052 @ $25.50 | EDGAR |
| 2025-11-10 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 29,131 @ $25.16 | EDGAR |
| 2025-10-06 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 4,207 @ $19.99 · Sale (S): 297 @ $20.78 | EDGAR |
| 2025-05-20 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 7,451 @ $14.07 | EDGAR |
| 2025-03-04 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 38,000 @ $0 · Grant/award (A): 17,000 @ $0 · Grant/award (A): 99,000 (derivative) @ $0 · Grant/award (A): 43,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 2,173 @ $12.70 | EDGAR |
| 2024-12-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Purchase (P): 1,093 @ $7.11 | EDGAR |
| 2024-10-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 3,725 @ $10.01 | EDGAR |
| 2024-05-20 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 60,000 @ $0 · Sale (S): 7,640 @ $8.98 | EDGAR |
| 2024-01-17 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 28,000 @ $0 · Grant/award (A): 176,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1994805 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →